Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov:10 Suppl:C215-7.
doi: 10.4103/0973-1482.145878.

Serum cyfra21-1 as a biomarker in patients with nonsmall cell lung cancer

Hongjie Zhao, Xuejun Shi, Jinbo Liu, Zhengang Chen, Guangshun Wang  1
Affiliations
Free article

Serum cyfra21-1 as a biomarker in patients with nonsmall cell lung cancer

Hongjie Zhao et al. J Cancer Res Ther. 2014 Nov.
Free article

Abstract

Objective: The purpose of this retrospective study was to evaluate the clinical value of serum cytokeratin-19-fragment (cyfra21-1) as a biomarker in nonsmall cell lung cancer (NSCLC).

Methods: Sixty-six patients with NSCLC and 48 cases with benign lung disease were retrospectively analyzed in the department of thoracic surgery in our hospital. The serum level of cyfra21-1 was detected in the above patients. The diagnosis sensitivity, specificity and the receiver operating characteristic curve were calculated by using the stata11.0 statistical software to evaluate the clinical diagnosis value of serum Cyfra21-1 as NSCLC serologic biomarker.

Results: The mean of serum cyfra21-1 were 8.95 eat. 01 μ/L and 4.28 eat. 89 μ/L in NSCLC patient and control groups respectively, which indicated that the NSCLC group were much higher (P < 0.05). The diagnosis sensitivity and specificity were 77.08% and 63.64% at the threshold of 6.32 μ/L respectively. Moreover, the area under the curve was 0.78 (95% confidence interval: 0.70-0.87).

Conclusion: Serum cyfra21-1 can be a potential serologic biomarker in evaluation of NSCLC.

PubMed Disclaimer